IRX-2

Summary

IRX-2 is an investigational biologic composed of a mixture of human cytokines (including IL‑2, IL‑1β, IFN‑γ and TNF‑α) derived from stimulated peripheral‑blood mononuclear cells. It is being studied as a neoadjuvant immunotherapy for resectable head and neck squamous‑cell carcinoma, particularly oral cavity cancer, with the aim of reversing tumor‑induced immune suppression and enhancing anti‑tumor immune activity before surgery.

Mechanism of Action

IRX‑2 delivers physiologic levels of multiple Th1‑type cytokines that act on dendritic cells, T‑lymphocytes and natural‑killer cells. The mixture promotes dendritic‑cell maturation, augments T‑cell proliferation and differentiation, and counteracts tumor‑mediated apoptosis of immune cells. In patients, this results in increased infiltration of CD8⁺ cytotoxic T cells and other lymphocytes into the tumour microenvironment, while not expanding regulatory T cells, thereby shifting the balance toward tumour‑directed immunity.

What the Research Shows

Early clinical investigations have shown immunologic and clinical activity of IRX‑2 in head and neck cancer. A randomized phase II trial (INSPIRE) in 96 oral‑cavity SCC patients reported a significant rise in CD8⁺ tumour‑infiltrating lymphocytes and a higher proportion of immune responders (74% vs 31% control). A phase IIA study of 27 resectable HNSCC patients demonstrated increased tumour infiltration by T, B and dendritic cells, radiologic tumour shrinkage, 2‑year event‑free survival of 64% and 5‑year overall survival of 65%. A pilot 1997 study of 20 patients observed major clinical responses in six, histologic tumour reduction averaging 44%, and marked lymphocyte count increases. Pre‑clinical work indicated reversal of thymic involution and synergistic effects when combined with thymosin α1. Peripheral blood analyses after IRX‑2 showed decreased circulating B and NKT cells, suggesting tissue redistribution, with unchanged regulatory T‑cell frequencies.

Reported Benefits

Evidence from early‑phase trials suggests IRX‑2 can increase tumour‑infiltrating CD8⁺ T cells and overall lymphoid infiltration, which correlates with tumour regression in a subset of patients. Reported clinical outcomes include partial or complete responses in some neoadjuvant settings and promising survival rates (64% event‑free at 2 years, 65% overall at 5 years) in a small cohort. The regimen appears to restore immune competence without expanding suppressive regulatory T cells, potentially enhancing anti‑tumour immunity.

Limitations of the Evidence

Findings are limited to small, early‑phase and single‑institution studies; no large, multicentre phase III data exist. Reported survival benefits are derived from modest sample sizes and lack a definitive control arm in some reports. The majority of data pertain to head and neck cancers only, and the durability of immune responses beyond the neoadjuvant window remains unclear. Potential variability in cytokine composition and lack of standardized dosing further constrain generalisability.

Safety Considerations

Across the published trials, IRX‑2 was well tolerated, with no major toxicities reported despite intensive perilymphatic dosing. Total peripheral lymphocyte counts remained stable, and regulatory T‑cell frequencies were unchanged. Minor laboratory changes included reductions in circulating B and NKT cells, interpreted as redistribution rather than depletion. However, comprehensive safety profiling is incomplete, and adverse‑event data from larger populations are not yet available.

How It Is Administered

IRX‑2 is administered as part of a 21‑day neoadjuvant regimen. Patients receive low‑dose cyclophosphamide followed by ten daily perilymphatic (regional) injections of the cytokine mixture, with concurrent oral indomethacin, zinc and omeprazole. Intravenous delivery has also been listed as a possible route, but clinical studies have focused on the perilymphatic injection schedule.

Routes of Administration

Goals & Uses

• Neoadjuvant immunotherapy prior to surgeryPerioperative OncologyModerate
• Combination with checkpoint inhibitorsOncologyLow
• Restoration of cancer-induced immune suppressionImmunomodulationModerate
• Anti-tumor immunotherapy in HNSCCOncology / ImmunotherapyModerate

Contraindications

• Active uncontrolled infectionInfectious DiseaseHigh
• Organ transplant recipients on immunosuppressionTransplantHigh
• Active autoimmune diseaseAutoimmunityHigh

Adverse Effects

• Hypersensitivity reactionsImmunologicRare
• Flu-like symptomsSystemic/ImmunologicalCommon
• Cytokine release syndromeImmunologicRareSystemic inflammatory response from immune activation
• Injection site reactionsLocalCommon
• LymphadenopathyLymphoreticularUncommon

Drug Interactions

• PD-1/PD-L1 checkpoint inhibitorsLow
• Immunosuppressive agents (e.g., methotrexate, azathioprine)High
• CorticosteroidsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with HIV or other immunodeficiencyImmunologicalRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization; clinical trials conducted under national CTAs in EU member states.
• United StatesInvestigationalFDA Fast Track designation granted for HNSCC. IND active. Not approved for any indication.
• United KingdomInvestigationalNo MHRA approval. Investigational status only.

IRX-2 has received FDA Fast Track designation for treatment of head and neck squamous cell carcinoma. It remains investigational and has not received FDA, EMA, or MHRA marketing approval. Manufactured under controlled GMP conditions from human donor PBMCs.

Evidence & Sources

• Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial
  Journal ArticleModerateWolf GT, et al.2020-01-01T00:00:00.000000Z
• IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers
  Journal ArticleModerateWolf GT, et al.2018-01-01T00:00:00.000000Z
• Immunodeficiency and cancer: prospects for correction
  Journal ArticleModerateHadden JW2003-01-01T00:00:00.000000Z
• A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer
  Journal ArticleModerateVerastegui E, et al.1997-01-01T00:00:00.000000Z
• Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy
  Journal ArticleModerateNaylor PH, Hadden JW2010-01-01T00:00:00.000000Z
• A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma
  Journal ArticleModerateWhiteside TL, et al.2012-01-01T00:00:00.000000Z

Frequently Asked Questions